Maximising Product Value and Strengthening the Sales Platform
First written in FY2017. 8 of 14 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2019: 1 of 7 companies on the "Worse" side.
4 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In March 2025, we relaunched our website for healthcare professionals and established KAKEN Medical Pro, including members-only content. As an information-provision platform using digital technology, we will create solutions tailored to the needs of healthcare professionals.」
As a measure to strengthen the sales platform, the Company established KAKEN Medical Pro, a members-only digital information platform for healthcare professionals. - FY2026-H1AdvancedAnnual report
「Kaken Pharma Co., Ltd., a consolidated subsidiary, launched an authorised generic (AG) of Crenafin.」
Crenafin reached the launch of an authorised generic by a consolidated subsidiary. Increased sales of Ecloc and other products were also reported. - FY2024-Q3RestatedAnnual report
「During the nine-month period of the current consolidated fiscal year, we launched a Twist Bottle in June 2023 as a new container for Ecloc, the primary axillary hyperhidrosis treatment, allowing the drug to be applied directly to the axilla, and launched Nexobrid, an agent for removing necrotic tissue, in August 2023.」
The launch of Ecloc's Twist Bottle and Nexobrid reconfirms the product-value enhancement and sales initiatives reported in the previous quarter. - FY2024-Q2RestatedAnnual report
「In June 2023, we launched a Twist Bottle that allows the drug to be applied directly to the axilla as a new container for Ecloc, the primary axillary hyperhidrosis treatment.」
The launch of Ecloc's Twist Bottle and the increase in Ecloc sales continue to be reported. - FY2024-Q1AdvancedAnnual report
「Sales increased for the primary axillary hyperhidrosis treatment Ecloc, for which a new Twist Bottle container was launched on 1 June, and the joint-function-improving agent Alz, among others. However, sales declined for the absorbable adhesion barrier Seprafilm and the onychomycosis treatment Crenafin, among others, due to the impact of competing products and drug price revisions, resulting in lower revenue.」
The Twist Bottle, a new container for Ecloc, was launched on 1 June, and increased sales of Ecloc, Alz and other products were reported. - FY2022RestatedAnnual report
「We will also advance the deployment of personnel and the development of organisational structures aligned with product characteristics and therapeutic areas, actively use ICT (information and communications technology), and provide high-value-added information that responds flexibly to changes in the needs of medical professionals and regulatory changes.」
The Company continues to strengthen its sales platform through product- and therapeutic-area-based personnel deployment, organisational development, and information provision using ICT. - FY2022-Q3RestatedAnnual report
「Information activities by medical representatives (MRs) and others are being conducted in line with the needs of healthcare professionals, using digital tools and other resources. When visiting medical institutions, we are implementing adequate infection-control measures.」
The Company continues to provide information to healthcare professionals using digital tools and conduct visits with infection-control measures in place. - FY2022-Q2RestatedAnnual report
「Information activities by medical representatives (MRs) and others are being conducted in line with the needs of healthcare professionals, using digital tools and other resources. When visiting medical institutions, we are implementing adequate infection-control measures.」
The Company continues to provide information to healthcare professionals using digital tools and conduct visits with infection-control measures in place. - FY2021AdvancedAnnual report
「We will also advance the deployment of personnel and the development of organisational structures aligned with product characteristics and therapeutic areas, actively use ICT (information and communications technology), and provide high-value-added information that responds flexibly to changes in the needs of medical professionals and regulatory changes.」
Specific measures to strengthen the sales platform were set out, including product- and therapeutic-area-based personnel deployment, organisational development, and the provision of information using ICT. - FY2021-Q3RestatedAnnual report
「Information activities by medical representatives (MRs) and others are being conducted in line with the needs of healthcare professionals, using digital tools and other resources.」
The sales initiative of using digital tools to provide information to healthcare professionals continues to be described, following the previous quarter. - FY2021-Q2AdvancedAnnual report
「Information activities by medical representatives (MRs) and others are being conducted in line with the needs of healthcare professionals, using digital tools and other resources.」
Specific measures were set out for sales and information activities, including the use of digital tools in addition to conventional visits. - FY2019RestatedAnnual report
「To maximise Crenafin's value in Japan, amid intensifying competition, we are working to strengthen and improve the efficiency of our sales platform while promoting overseas expansion.」
The Company continues to strengthen and improve the efficiency of its domestic sales platform and maximise Crenafin's value through overseas expansion. - FY2018RestatedAnnual report
「In Japan, amid intensifying competition, we are working to strengthen and improve the efficiency of our sales platform while promoting overseas expansion.」
The policy of strengthening and improving the efficiency of the sales platform to maximise Crenafin's value, together with overseas expansion, continues to be stated. - FY2017First statedAnnual report
「In sales, we will provide high-value-added information tailored to the needs of medical professionals and develop a community-based sales operation. We will further consolidate our position in orthopaedics while increasing our presence in dermatology. We will also use product-related websites, mass media and other channels to disseminate information.」
The Company set out a policy of maximising the value of Crenafin and new products and strengthening the sales platform for existing products through community-based sales, the provision of value-added information, and the use of websites and mass media.